The Japan patent office has issued a patent that protects the manufacturing processes for KAND567 and KAND145
Kancera reports that patient enrollment to the FRACTAL-study is completed and that top line results will be presented in Q3 2023
Interim Report Fourth Quarter 2022 January 1 – December 31 2022 Kancera AB (publ.), org.nr. 556806-8851
Kancera reports that the Swedish Medical Products Agency has approved the application to conduct the KANDOVA-study and that Dr. Hanjing Xie has been appointed to Chief Medical Officer
